• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?

Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?

May 4, 2021
Nicholas Rosenlicht, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Kishi T et al, Psychol Med 2020 Oct 13:1–9; PMID: 33046156


Type of study: Meta-analysis of double-blind, randomized placebo-controlled trials


Bipolar disorder is a lifelong illness whose treatment is an ongoing challenge, complicated not least by difficulties in treatment adherence. What do we know and what can we tell our patients about how long to continue medication?


This meta-analysis looked at recurrence rates of any mood episode in bipolar disorder after 6 months of maintenance treatment vs discontinuation of medication. The authors analyzed 22 double-blind, placebo-controlled studies of second-generation antipsychotics (LAI or oral) or a mood stabilizer in adults with bipolar I or II disorder that included a maintenance phase lasting at least 12 weeks. Some studies recruited stable subjects, while others were extensions of acute treatment studies after initial stabilization. Results were also broken down by relapse into episode subtypes: depressive, manic/hypomanic/mixed, as well as all-cause discontinuation from the study.


Compared to drug discontinuation, maintenance treatment was associated with a lower recurrence rate at 6 months for all mood episodes. The relative risks (RR) for those who remained on medication were 0.61 for any episode, 0.72 for depressive episodes, 0.45 for manic/hypomanic/mixed episodes, and 0.71 for all-cause discontinuation. The raw relapse rates into any mood episode at 6 months were 32.3% with maintenance vs 52.7% with discontinuation. In subgroup analyses, oral second-generation antipsychotics had better preventative properties than lithium or lamotrigine, based on their RRs. However, all but one of the eight SGA studies (nine groups) were “enriched”—that is to say, they included only subjects who had proven to be responsive to medication—while only two of the 15 lithium studies were enriched, making direct comparisons invalid. Oral antipsychotics were superior to long-acting injectables at preventing depression, which is not surprising considering none of the FDA-approved options for bipolar depression (cariprazine, lurasidone, quetiapine, and olanzapine-fluoxetine combination) are available in injectable form.


One limitation is the possibility that some of these relapses represented withdrawal phenomena, as most studies discontinued the medication abruptly. Also, the majority of relapses occurred at the very beginning of the follow-up period, which raises the possibility that withdrawal effects contributed to the relapse risk.


TCPR’s TAKE
Long-term maintenance medication is the norm in bipolar disorder, and this study backs up that standard. When patients want to stop their primary mood stabilizer, we can advise them that they are twice as likely to stay well if they stick with it. It may be feasible to come off an augmentation agent, however, if they have been well for at least 6 months and keep the primary mood stabilizer on board (see TCPR Jan 2020 on antipsychotic maintenance). Slow discontinuation (eg, over 1–6 months) also reduces the relapse risk, particularly with lithium.



podcastsTo learn more, listen to our 5/31/21 podcast, “Punk Rock, Barbiturates, and Bipolar Disorder.” Search for “Carlat” on your podcast store.


General Psychiatry
KEYWORDS bipolar-depression bipolar-ii bipolar_disorder lithium medication-adherence mood_stabilizers retention
Nicholas Rosenlicht, MD.

Listening to Depression: The Importance of Addressing Hearing Loss

More from this author
www.thecarlatreport.com
Issue Date: May 4, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Problems with Generics, TCPR, May 2021
In Brief: Lamotrigine Gets a New Warning
A Review of Medications for PTSD, With a Focus on Topiramate
What’s Wrong With Generics?
Depression, Vitamin D, and COVID-19
Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.